多学科联合治疗已经成为晚期头颈癌的标准治疗,不但可以延长生存时间,还能够改善术后生活质量。分子靶向药物治疗已经成为晚期头颈癌多学科联合治疗的重要组成部分。西妥昔单抗能够降低晚期头颈鳞癌患者的局部复发率和远处转移率。近年来,西妥昔单抗的临床试验在欧美已经开始。研究发现,西妥昔单抗联合放疗(RT)在降低患者的局部复发率及提高总生存率(OS)方面显著优于单独RT。目前,临床 Multidisciplinary combination therapy has become the standard treatment for advanced head and neck cancer, not only to extend the survival time, but also to improve postoperative quality of life. Molecular targeted drug therapies have become an important part of multi-disciplinary combination therapy for advanced head and neck cancer. Cetuximab can reduce the local recurrence rate and distant metastasis rate in patients with advanced head and neck squamous cell carcinoma. In recent years, clinical trials of cetuximab have begun in Europe and the United States. The study found that cetuximab combined with radiotherapy (RT) was significantly better than the single RT in reducing the local recurrence rate and increasing the overall survival rate (OS). At present, clinical